课题基金 / 基金详情

Combined IAP antagonism and immunotherapy for cancer treatment

Combined IAP antagonism and immunotherapy for cancer treatment
IAP 拮抗和免疫疗法联合治疗癌症
批准号：
381632
负责人：
Korneluk Robert G
金额：
$68.27万
依托单位：
Children's Hospital of Eastern Ontario- Ottawa Children's Treatment Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-03-01 至 2023-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=381632&lang=en
关键词：
Apoptosis Bladder Cancer Cancer Immunotherapy Combination Synergy Cytotoxic T Lymphocyte Iap Antagonists Immune Checkpoint Inhibitors Smac Mimetics Tnfalpha Tumor Immunity

项目摘要

项目成果

Korneluk Robert G的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Immunotherapy is currently an effective and viable treatment for several cancers and this approach complements the existing standard treatment modalities of surgery, radiation and chemotherapy. The recent successes of immunotherapy agents (known as immune
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of the Inhibitors of Apoptosis (IAPs) in health and disease
Combination of IAP antagonism and immune checkpoint blockade to treat brain cancer
Combined IAP antagonism and immunotherapy for cancer treatment
Role of cellular Inhibitors of Apoptosis (cIAPs) in muscle biology and disease
海外基金